CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.
  
  LEARNING OBJECTIVES

  • Consider the clinical utility of minimal residual disease (MRD) assessment and how it can inform treatment decisions for patients with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM).
  • Understand the similarities and differences among available methodologies for assessing MRD status in patients with CLL or MM.
  • Appraise published research data validating the use of MRD status to assess response to active therapy and to identify disease recurrence, and use this information to determine the potential role of MRD assays in the protocol and nonresearch management of MM and CLL.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/OncologyTodayMRD21/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Shaji K Kumar, MD
  Mark and Judy Mullins Professor of Hematological Malignancies
  Consultant, Division of Hematology
  Professor of Medicine
  Mayo Clinic
  Rochester, Minnesota
  
  Consulting/Advisory Board: Antengene, BeiGene Ltd, Oncopeptides; Consulting/Advisory Board (no personal payments): AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Takeda Oncology; Research Funding for Clinical Trials to the Institution: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, CARsgen Therapeutics, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Oncology, TeneoBio.
  
  Philip A Thompson, MB, BS
  Assistant Professor, Department of Leukemia
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: AbbVie Inc, Adaptive Biotechnologies Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, VelosBio Inc; Other: CME talks sponsored by Janssen Biotech Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Adaptive Biotechnologies Corporation.
  
  Release date: March 2021
  Expiration date: March 2022
  
  After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.